Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Cash from Financing Activities of $6.1 million for Q1 2026, up 40.92% quarter-over-quarter from $4.3 million in Q4 2025.
Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Cash from Financing Activities for 6 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $16.3 million (changed N/A YoY), while the FY2025 annual figure was $18.6 million, up 3.82% from the prior year.
- Cash from Financing Activities advanced to $6.1 million in Q1 2026 per VVOS's latest filing, from $4.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $7.4 million in Q2 2024 and bottomed at $2.8 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged $4.7 million across 4 years, with a median of $3.8 million in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 50.58% — and 2025, when it jumped 41.94%.
- Vivos Therapeutics' Cash from Financing Activities stood at $3.6 million in 2023, then slipped by 14.41% to $3.1 million in 2024, then jumped by 41.94% to $4.3 million in 2025, then soared by 40.92% to $6.1 million in 2026.
- Business Quant data shows VVOS's Cash from Financing Activities at $6.1 million in Q1 2026, $4.3 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Vivos Therapeutics | 4.94 Mn | 3.14 Mn | 2.95 Mn | 3.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.11 Mn |
| Mar 31, 2026 | 6.11 Mn |
| Dec 31, 2025 | 4.34 Mn |
| Dec 31, 2025 | 4.34 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Dec 31, 2024 | 3.05 Mn |
| Dec 31, 2024 | 3.05 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Mar 31, 2024 | 3.64 Mn |
| Mar 31, 2024 | 3.64 Mn |
| Dec 31, 2023 | 3.57 Mn |
| Dec 31, 2023 | 3.57 Mn |
| Mar 31, 2023 | 7.36 Mn |
| Mar 31, 2023 | 7.36 Mn |
| Sep 30, 2021 | -1.17 Mn |
| Sep 30, 2021 | -1.17 Mn |